RBC Capital analyst Brian Abrahams raised the firm’s price target on Regeneron to $806 from $787 but keeps a Sector Perform rating on the shares. The analyst states that the firm’s statistical deep dive suggests "high likelihood" that the company’s upcoming phase 3 COPD trial will "hit", and its success could considerably de-risk an additional $3.4B and $1.1B of out-year sales and profit opportunity. The firm adds that its statistical model constructed alongside that of experts showed that having passed through a futility analysis, dupilumab likelihood of ultimately showing statistical significance may be 83%, though its neutral stance on the stock reflects a cap on potential upside for Regeneron as its Eylea dynamics are still uncertain.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron, Sanofi announces FDA acceptance for review of Dupixent sBLA
- Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
- Regeneron and Sanofi’s Kevzara approved by FDA for polymyalgia rheumatica
